APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/06/2022 | 04:05pm EDT

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 3, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 0 Inducement Stock Incentive Plan) and material to the employee’s acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employee received options to purchase 60,000 shares of Apellis common stock and 20,000 restricted stock units (RSUs). The options have an exercise price of $48.77, which is equal to the closing price of Apellis common stock on January 3, 2022, the grant date of the options. One-fourth of the shares underlying the employee options will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the employee options will vest monthly, such that the shares underlying the options granted to the employee will be fully vested on the fourth anniversary of the grant date, subject to the employee’s continued employment with Apellis on such vesting dates. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the company’s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company’s clinical trials will warrant regulatory submissions and whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2020 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178 


Primary Logo

Source: Apellis Pharmaceuticals, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about APELLIS PHARMACEUTICALS, INC.
05/24Goldman Sachs Adjusts Apellis Pharmaceuticals' Price Target to $84 from $94, Keeps Buy ..
MT
05/20Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $49 from $44, Maintains N..
MT
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
GL
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
AQ
05/11TRANSCRIPT : Apellis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
05/05Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Co..
GL
05/05Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $102 from $114, Keeps St..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 92,9 M - -
Net income 2022 -579 M - -
Net cash 2022 420 M - -
P/E ratio 2022 -7,63x
Yield 2022 -
Capitalization 4 533 M 4 533 M -
EV / Sales 2022 44,3x
EV / Sales 2023 15,1x
Nbr of Employees 476
Free-Float 83,0%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 42,55 $
Average target price 71,73 $
Spread / Average Target 68,6%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-10.00%4 533
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%21 450